Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 5Breast Neoplasms 3Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thyroid Diseases 1Rectal Neoplasms 1Prostatic Neoplasms 1Patient Preference 1Patient Acceptance of Health Care 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Lymphoma 1Lung Neoplasms 1Gastrointestinal Neoplasms 1

Interventions

Oxaliplatin 29Fluorouracil 25Leucovorin 20Capecitabine 18Irinotecan 17Surveys and Questionnaires 16Bevacizumab 14Cisplatin 12Blood Specimen Collection 11Drug Therapy 10Standard of Care 9Nivolumab 9Gemcitabine 9Cetuximab 7pembrolizumab 6Specimen Handling 6S 1 (combination) 6Endoscopic Mucosal Resection 6Cyclophosphamide 6atezolizumab 5Sunitinib 5Radiotherapy 5Folfox protocol 5Educational Status 5Docetaxel 5fludarabine 4aldesleukin 4Radiosurgery 4Pemetrexed 4Magnetic Resonance Spectroscopy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Neoplasms × Focus Groups × Gastrointestinal × Clear all
NCT06559462 2025-11-25

DPYD Nudges

Abramson Cancer Center at Penn Medicine

Phase NA Completed
50 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Patient Acceptance of Health Care

Data powered by HemOnc (CC BY 4.0) Colophon âš¡